Captor Therapeutics SA
WSE:CTX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Captor Therapeutics SA
Revenue
Captor Therapeutics SA
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
Captor Therapeutics SA
WSE:CTX
|
Revenue
zł15.8m
|
CAGR 3-Years
58%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
M
|
Marvipol Development SA
WSE:MVP
|
Revenue
zł547.7m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
|
M
|
MLP Group SA
WSE:MLG
|
Revenue
zł401.4m
|
CAGR 3-Years
17%
|
CAGR 5-Years
18%
|
CAGR 10-Years
14%
|
|
|
L
|
Lokum Deweloper SA
WSE:LKD
|
Revenue
zł106.4m
|
CAGR 3-Years
-34%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-2%
|
|
|
C
|
CFI Holding SA
WSE:CFI
|
Revenue
zł257.9m
|
CAGR 3-Years
20%
|
CAGR 5-Years
8%
|
CAGR 10-Years
36%
|
|
|
D
|
Develia SA
WSE:DVL
|
Revenue
zł2.1B
|
CAGR 3-Years
25%
|
CAGR 5-Years
32%
|
CAGR 10-Years
17%
|
|
Captor Therapeutics SA
Glance View
Captor Therapeutics SA engages in the development of protein degradation drugs for cancer and autoimmune diseases. The company is headquartered in Wroclaw, Woj. Dolnoslaskie and currently employs 98 full-time employees. The company went IPO on 2021-04-19. The firm works in the field of neoplastic and autoimmune diseases for which there is no treatment option, or the available methods show therapeutic limitations. The firm covers aspects of early-stage drug development to deliver therapeutics for life-threatening and life-impairing diseases. The broadly applicable Optigrade tm Targeted Protein Degradation (TPD) platform allows for the creation of new drugs.
See Also
What is Captor Therapeutics SA's Revenue?
Revenue
15.8m
PLN
Based on the financial report for Dec 31, 2024, Captor Therapeutics SA's Revenue amounts to 15.8m PLN.
What is Captor Therapeutics SA's Revenue growth rate?
Revenue CAGR 3Y
58%
Over the last year, the Revenue growth was 20%. The average annual Revenue growth rates for Captor Therapeutics SA have been 58% over the past three years .
